HEADLINE

Marty Makary confirmed as 27th FDA Director after Senate vote; his approach to e-cigarettes and healthcare policies under scrutiny.

Former BAT innovation executive Chris Gemmell explains how innate limitations can help product developers understand and solve problems.

As the FDA tightens NGP regulations, the U.S.—the world’s largest market—is undergoing a seismic shift, with the industry facing a potential reset. As a leading authority on FDA’s PMTA process, CSUR brings deep expertise in regulatory science and consumer behavior analytics. Dr. Patton discusses shifting FDA priorities, the role of behavioral science in PMTA approvals, and how businesses can balance compliance with market competitiveness amid industry restructuring.

Russia’s NGPs market is set for 20% growth in 2025, but regulatory pressures and a dominant illicit sector pose challenges. In a 2Firsts exclusive, Fedotov Group’s Evgeny Fedotov shares insights on PMI’s HTP dominance, ENDS shifts, and China’s growing role. Can legal brands stay ahead?

Synthetic nicotine is reshaping the industry, sparking debates on regulation, science, and market impact. In this 2Firsts interview, Dr. Pete Gibbons of Labstat International breaks down the key challenges and what lies ahead.